Promising clinical trial data in the setting of HER-2 overexpressing breast cancer support the principle combining baseline target-specific immuno-PET/CT imaging with early assessment of tumor metabolism using [18F]FDG-PET/CT to identify the subset of patients who will benefit from the treatment [4]. This evidence concerns the gene ERBB2 and breast cancer.